Explore the words cloud of the BeVision project. It provides you a very rough idea of what is the project "BeVision" about.
The following table provides information about the project.
Coordinator |
VOPTICA S.L.
Organization address contact info |
Coordinator Country | Spain [ES] |
Project website | http://www.voptica.com |
Total cost | 2˙486˙788 € |
EC max contribution | 1˙740˙751 € (70%) |
Programme |
1. H2020-EU.3.1.4. (Active ageing and self-management of health) 2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.1.6. (Health care provision and integrated care) |
Code Call | H2020-SMEINST-2-2016-2017 |
Funding Scheme | SME-2 |
Starting year | 2017 |
Duration (year-month-day) | from 2017-11-01 to 2020-04-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | VOPTICA S.L. | ES (MURCIA) | coordinator | 1˙740˙751.00 |
As we get older, we all will develop eyesight problems. Around the age of 65 more than half of us suffer from eye lens clouding, or cataracts. Cataract surgery is now the most common operation in Europe, with 4.3 million people getting treated each year, a figure that will only increase due to our fast aging population. However, 200,000 of them are not satisfied with the outcome of their eye correcting surgeries as they can’t experience on forehand what their vision will be. Voptica has developed the Visual Adaptive Optics (VAO) simulator, a disruptive innovation in eye testing, allowing patients to experience the effect of intraocular lenses or laser surgery on their vision before the actual operation, helping the patient and doctor to select their best solution and understand what their vision will be like post-surgery.
Our technology is used by world-leading research institutes and lens-manufactures, but to prepare VAO for clinical market introduction our project BeVision will refine its software protocols, make it interoperable and clinically validate the technology. After a successful clinical validation, VAO will be the only medical device in the world that can measure objectively all eye aberrations of patients and, subsequently, simulate the different optical solutions to correct the patient’s eye imperfections during visual testing. Our technology will dramatically improve the outcomes of cataract and laser refractive surgeries.
Our highly competitive technology can swiftly disrupt the $4.4 billion ophthalmology device market, generating a rapid business growth for Voptica, with a cumulative revenue of € 36.4m and a profit of € 8.6m by 2025.
To make BeVision a commercial success, we have assembled a consortium with a solid track record in the development, optimisation, clinical validation and commercialisation of ophthalmic devices and have all the skills and resources for its commercial exploitation to benefit our business and Europe.
WP4 Scientific publications | Documents, reports | 2020-03-09 16:07:04 |
Take a look to the deliverables list in detail: detailed list of BeVision deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BEVISION" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BEVISION" are provided by the European Opendata Portal: CORDIS opendata.
CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research
Read MoreBioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously
Read MoreSensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.
Read More